Skip to main content
Midas Edge

OnKure Therapeutics, Inc.

For the period ended Jun 30, 2025. Filed Aug 12, 2025.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2025 · Filed Aug 12, 2025

OKUR$2.87+13.5%Stored close · as of Nov 6, 2026
See the whole filing, with its images and exhibits
Contents

Condensed Consolidated Balance Sheets

(in thousands, except share and per share data)

June 30,December 31,
20252024
ASSETS
Current assets:
Cash and cash equivalents$83,374$110,761
Prepaid expenses and other current assets1,1782,242
Total current assets84,552113,003
Property and equipment, net8211,025
Operating lease right-of-use asset581770
Other assets116109
Total assets$86,070$114,907
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Accounts payable$2,381$2,968
Accrued expenses4,6607,026
Operating lease liabilities, current portion556536
Total current liabilities7,59710,530
Long-term operating lease liabilities267549
Other long-term liabilities40—
Total liabilities7,90411,079
Commitments and contingencies
Stockholders’ equity:
Common stock, Class A, $0.0001 par value; 200,000,000 shares authorized; 12,843,434 and 12,660,590 shares issued and outstanding at June 30, 2025 and December 31, 2024, respectively11
Common stock, Class B, $0.0001 par value; 10,000,000 shares authorized; 686,527 shares issued and outstanding at both June 30, 2025 and December 31, 2024——
Additional paid-in capital264,204258,551
Accumulated deficit(186,039)(154,724)
Total stockholders’ equity78,166103,828
Total liabilities and stockholders’ equity$86,070$114,907
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.